



# ECICC Framework Quality Assurance Steps

## CONSENT STATEMENT

Thank you for all of your work over the past three days here in Ispra!

You are being invited to participate in a survey to prioritize steps in the development of guideline-based quality assurance scheme for the forthcoming European Commission’s Initiative on Colorectal Cancer (ECICC). This survey is part of an official methodological framework commissioned by the European Commission. Your input will inform the **development of the methodological framework** to prepare for the ECICC.

By completing this survey, you consent to your response being collected to be used for the methodological framework.

Disclaimer: While the ECICC will be informed by this survey, the **related mandate to eventually conduct the work on the guidelines and quality assurance scheme** will not be affected by the results of this survey.

## Instructions:

We would like to obtain your views on the considerations and steps for guideline-based quality assurance scheme development. In completing the following questions, please consider the existing steps in guideline-development from the GIN-McMaster Guideline Development Checklist, which is available here:

<http://heigrade.mcmaster.ca/guideline-development/gin-mcmaster-guideline-development-checklist/using-checklist>

The steps that are recommended in this survey will inform additions to the GIN-McMaster Guideline Development Checklist for guideline-based quality assurance scheme development.

We realize that you may not be able to answer all questions or that you have more expertise in some than in other areas. Please do answer the questions to the best of your ability following your evaluation of the circulated feasibility plan. Should you have any questions or concerns please contact Dr. Holger Schünemann at [holger.schunemann@mcmaster.ca](mailto:holger.schunemann@mcmaster.ca) or Dr. Miranda Langendam at [m.w.langendam@amc.uva.nl](mailto:m.w.langendam@amc.uva.nl).

It is estimated that this survey will take between 20-30 minutes to complete and will begin with questions about your background. With your consent, we may contact you to follow-up on any responses that we would like further clarification on.

## Questions:

**For each of the following NEW items please state your agreement (from strongly disagree to strongly agree) with their inclusion as part of a quality assurance extension to the Checklist.**

**\* 1. Organization, Budget, Planning and Training (although general here, it will be specifically based on the scope for the ECICC in the final framework)**

			Neither			
Strongly		Somewhat	agree or	Somewhat		Strongly
Disagree	Disagree	Disagree	disagree	Agree	Agree	Agree



				Neither			
Strongly		Somewhat	agree or	Somewhat			Strongly
Disagree	Disagree	Disagree	disagree	Agree	Agree	Agree	Agree

7. Decide if the evaluation of a quality indicator is an intervention question (e.g. Does the use of informed choice interventions compared to not using informed choice improve net consequences as opposed to using informed choice as a quality indicator of a conditional recommendation).

<input type="radio"/>							
-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------

**\* 6. Consumer and Stakeholder Involvement**

				Neither			
Strongly		Somewhat	agree or	Somewhat			Strongly
Disagree	Disagree	Disagree	disagree	Agree	Agree	Agree	Agree

10. Allow relevant stakeholders to be part of the consultation process.

<input type="radio"/>							
-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------

**\* 7. Conflict of Interest (COI) Considerations**

				Neither			
Strongly		Somewhat	agree or	Somewhat			Strongly
Disagree	Disagree	Disagree	disagree	Agree	Agree	Agree	Agree

8. Apply the same DOI and COI management rules to GL and QA (healthcare institutions representatives may require specific considerations).

<input type="radio"/>							
-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------

9. Consider credibility of the institution in declaring what is known to individuals and what is not known at the time of declaration.

<input type="radio"/>							
-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------

**\* 8. (PICO) Question Generation**

				Neither			
Strongly		Somewhat	agree or	Somewhat			Strongly
Disagree	Disagree	Disagree	disagree	Agree	Agree	Agree	Agree

1b. A logical model/analytical pathway/disease model/analytical PICO framework should be produced beginning with prevention to diagnosis to treatment to the outcomes.

<input type="radio"/>							
-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------

14. Determine if outcomes are feasible and measurable and important for people either directly or indirectly for quality assurance purposes.

<input type="radio"/>							
-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------

15. If the recommendation relates to the evaluation of a QI, then the group should consider using an intervention framework EtD to assess the QI (PICO/Topic Selection).

<input type="radio"/>							
-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------

16. Identify all relevant input parameters from the different parts of the pathway to the overall patient important outcomes and quality indicators

<input type="radio"/>							
-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------	-----------------------

**\* 9. Considering Importance of Outcomes and Interventions, Values, Preferences and Utilities**

				Neither			
Strongly		Somewhat	agree or	Somewhat			Strongly
Disagree	Disagree	Disagree	disagree	Agree	Agree	Agree	Agree

	Strongly Disagree	Disagree	Somewhat Disagree	Neither agree or disagree	Somewhat Agree	Agree	Strongly Agree
10. Rate or select a small but sufficient number of candidate QIs. Consider their relation to the people important outcomes and are valid long-term surrogates.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
11. Consider QIs that cannot be manipulated by those parties that are affected by them.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
12. When considering candidate outcomes as QI, describe their relevance, the supporting evidence (scientific soundness), and feasibility.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
13. Consider the precision of a QI.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

**\* 10. Deciding what Evidence to Include and Searching for Evidence**

	Strongly Disagree	Disagree	Somewhat Disagree	Neither agree or disagree	Somewhat Agree	Agree	Strongly Agree
11. Evaluate if evidence supports that the use of a PM improves people outcomes.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
12. Check if there is evidence that certification and accreditation improves outcomes.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

**\* 11. Summarizing Evidence and Considering Additional Information**

	Strongly Disagree	Disagree	Somewhat Disagree	Neither agree or disagree	Somewhat Agree	Agree	Strongly Agree
8. Consider items relevant for the development of decision aids.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
9. Reconsider what quality assurance or performance indicators can be developed.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

**\* 12. Judging Quality, Strength or Certainty of a Body of Evidence (None Identified)**

**\* 13. Developing Recommendations and Determining their Strength (including considerations about quality assurance)**

	Strongly Disagree	Disagree	Somewhat Disagree	Neither agree or disagree	Somewhat Agree	Agree	Strongly Agree
11. Consider which outcomes are measurable, feasible and relevant as quality indicators or performance measures	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
12. Consider which outcomes are measurable, feasible, scientifically sound and relevant as quality indicators or performance measures etc. TO BE COMPLETED BAED ON CRITERIA.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

**\* 14. Wording of Recommendations and of Considerations of Implementation, Research, Monitoring and Evaluation (including considerations about quality assurance)**



**\* 18. Evaluation and Use (including considerations about quality assurance)**

	Strongly Disagree	Disagree	Somewhat Disagree	Neither agree or disagree	Somewhat Agree	Agree	Strongly Agree
7. Consider pilot testing the quality indicators and performance measures with the target end users (e.g. with members of target audience and stakeholders who participated in the development group).	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>
8. Consider providing guidance on when to 'retire' or cease measuring performance measure.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

**\* 19. Updating**

	Strongly Disagree	Disagree	Somewhat Disagree	Neither agree or disagree	Somewhat Agree	Agree	Strongly Agree
7. Reevaluate the quality indicators, performance measures and performance indicators.	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>	<input type="radio"/>

**20. What additional feedback do you have regarding the steps in quality assurance scheme development? Please reference the checklist section that is relevant if possible.**

**\* 21. What is your name?**

First Name

Last Name

**End of Questionnaire**

Thank you very much for your participation in this survey and for your feedback on the checklist considerations.

Done

